Making Medicines in America: How Congress Can Help America’s AI, Biopharma, and Manufacturing Industries Make It Happen

Logistical Note: In-person attendees should utilize the Southwest Dirksen entrance at the corner of First St NE and Constitution Ave NE. SD-106 is located directly after the elevator bank on the right hand side of the hallway when utilizing the Southwest entrance.

The United States faces a crisis in its pharmaceutical supply chain. Over 70 percent of active pharmaceutical ingredients are made overseas, with China dominating key supply chains and AI-driven manufacturing accelerating its lead. The consequences for Americans include record drug shortages, heightened national security risks, and soaring costs that threaten American patients and U.S. economic stability.

It’s time to take action. America has the technology, talent, and urgency to lead in next-generation drug manufacturing, and must make a strategic pivot toward pharmaceutical independence through economic revitalization and modernizing regulation to unshackle AI-driven innovation.

Watch now for a summit on Capitol Hill presented by ITIF, Purdue University, and the National Institute for Pharmaceutical Technology and Education (NIPTE) where top leaders in AI, pharmaceutical manufacturing, and public policy will discuss what must be done.

This historic program included:

• 1:35–1:45 PM: Opening Remarks by Stephen Ezell and Monique K. Mansoura
• 1:45–2:20 PM: Expert Panel Discussion moderated by Purdue University President Mung Chiang
• 2:20–2:25 PM: Remarks by Senator Todd Young (R-IN)
• 2:25–2:35 PM: Remarks by Eli Lilly and Company CEO David A. Ricks
• 2:35–2:40 PM: Purdue President Mung Chiang Announces Commencement of Historic Accord Signing
• 2:35–3:00 PM: Historic Accord Signing